Gabriel Etienne

Bordeaux, France

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 93 publications

Development and External Validation of a Transcriptome-Based Multivariable Prediction Model for Treatment-Free Remission in Chronic Myeloid Leukemia.

Development and External Validation of a Transcriptome-Based Multivariable Prediction Model for Treatment-Free Remission in Chronic Myeloid Leukemia.

Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology

Published: July 15, 2026

ASC4OPT: asciminib treatment optimization study in patients with chronic myeloid leukemia in chronic phase previously treated with two or more tyrosine kinase inhibitors.

ASC4OPT: asciminib treatment optimization study in patients with chronic myeloid leukemia in chronic phase previously treated with two or more tyrosine kinase inhibitors.

Journal: Leukemia

Published: March 20, 2026

Favorable tolerability of asciminib versus ATP-competitive tyrosine kinase inhibitors in the ASC4FIRST study of newly diagnosed patients with chronic-phase chronic myeloid leukemia.

Favorable tolerability of asciminib versus ATP-competitive tyrosine kinase inhibitors in the ASC4FIRST study of newly diagnosed patients with chronic-phase chronic myeloid leukemia.

Journal: Haematologica

Published: October 31, 2025

Randomized phase 3 trial of Ropeginterferon alfa-2b versus surveillance after tyrosine kinase inhibitor discontinuation in chronic myeloid leukemia (ENDURE/CML-IX).

Randomized phase 3 trial of Ropeginterferon alfa-2b versus surveillance after tyrosine kinase inhibitor discontinuation in chronic myeloid leukemia (ENDURE/CML-IX).

Journal: Leukemia

Published: October 28, 2025

Thromboinflammation is associated with high thrombotic risk in patients with newly diagnosed myeloproliferative neoplasms.

Thromboinflammation is associated with high thrombotic risk in patients with newly diagnosed myeloproliferative neoplasms.

Journal: Leukemia

Published: August 20, 2025

Thromboinflammation is associated with high thrombotic risk in patients with newly diagnosed myeloproliferative neoplasms.

Thromboinflammation is associated with high thrombotic risk in patients with newly diagnosed myeloproliferative neoplasms.

Journal: Leukemia

Published: August 20, 2025

Final results of nilotinib versus nilotinib combined with pegylated interferon alfa-2a as first-line therapy in chronic phase chronic myeloid leukaemia in France (PETALs): an open-label, multicentre, randomised phase 3 trial.

Final results of nilotinib versus nilotinib combined with pegylated interferon alfa-2a as first-line therapy in chronic phase chronic myeloid leukaemia in France (PETALs): an open-label, multicentre, randomised phase 3 trial.

Journal: The Lancet. Haematology

Published: August 18, 2025

Asciminib demonstrates superior efficacy and safety in newly diagnosed chronic myeloid leukemia in the ASC4FIRST trial.

Asciminib demonstrates superior efficacy and safety in newly diagnosed chronic myeloid leukemia in the ASC4FIRST trial.

Journal: Blood

Published: July 01, 2025

Asciminib Demonstrates Superior Efficacy and Safety in Newly Diagnosed Chronic Myeloid Leukemia in the ASC4FIRST Trial.

Asciminib Demonstrates Superior Efficacy and Safety in Newly Diagnosed Chronic Myeloid Leukemia in the ASC4FIRST Trial.

Journal: Blood

Published: July 01, 2025

Extended long-term follow-up and the survival of Stop Imatinib study.

Extended long-term follow-up and the survival of Stop Imatinib study.

Journal: Blood neoplasia

Published: February 10, 2025

Treatment-free remission in chronic myeloid leukemia with rare ABL1 gene fusions: Real-life study from the French CML group Fi-LMC.

Treatment-free remission in chronic myeloid leukemia with rare ABL1 gene fusions: Real-life study from the French CML group Fi-LMC.

Journal: Leukemia research

Published: February 05, 2025

Mutation of Epigenetic Regulators at Diagnosis Is an Independent Predictor of Tyrosine Kinase Inhibitor Treatment Failure in Chronic Myeloid Leukemia: A Report From the RESIDIAG Study.

Mutation of Epigenetic Regulators at Diagnosis Is an Independent Predictor of Tyrosine Kinase Inhibitor Treatment Failure in Chronic Myeloid Leukemia: A Report From the RESIDIAG Study.

Journal: American journal of hematology

Published: September 12, 2024

Showing 1-12 of 93

Last Updated: 09/26/2026